{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:46:18Z","timestamp":1780397178941,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"crossref","award":["2017-1938"],"award-info":[{"award-number":["2017-1938"]}],"id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s12325-019-01118-x","type":"journal-article","created":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T21:29:41Z","timestamp":1572038981000},"page":"3494-3502","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-7624","authenticated-orcid":false,"given":"Roberta","family":"Gualtierotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ingegnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Boscolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Griffini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Grovetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,25]]},"reference":[{"key":"1118_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023\u201338.","journal-title":"Lancet"},{"key":"1118_CR2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/nrrheum.2015.112","volume":"11","author":"MT Nurmohamed","year":"2015","unstructured":"Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol. 2015;11:693\u2013704.","journal-title":"Nat Rev Rheumatol"},{"key":"1118_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2174\/157016110790886965","volume":"8","author":"M Cugno","year":"2010","unstructured":"Cugno M, Ingegnoli F, Gualtierotti R, Fantini F. Potential effect of anti-tumour necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis. Curr Vasc Pharmacol. 2010;8:285\u201392.","journal-title":"Curr Vasc Pharmacol"},{"key":"1118_CR4","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","volume":"74","author":"C Roubille","year":"2015","unstructured":"Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74:480\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1118_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jaut.2008.07.002","volume":"31","author":"F Ingegnoli","year":"2008","unstructured":"Ingegnoli F, Fantini F, Favalli EG, Soldi A, Griffini S, Galbiati V, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun. 2008;31:175\u20139.","journal-title":"J Autoimmun"},{"key":"1118_CR6","first-page":"254","volume":"28","author":"F Ingegnoli","year":"2010","unstructured":"Ingegnoli F, Fantini F, Griffini S, Soldi A, Meroni PL, Cugno M. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. Clin Exp Rheumatol. 2010;28:254\u20137.","journal-title":"Clin Exp Rheumatol"},{"key":"1118_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23875","author":"S Singh","year":"2019","unstructured":"Singh S, Fumery M, Singh AG, Singh N, Prokop LJ, Dulai PS, et al. Comparative risk of cardiovascular events with biologic and synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2019. \nhttps:\/\/doi.org\/10.1002\/acr.23875\n\n.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1118_CR8","first-page":"451","volume":"34","author":"R Gualtierotti","year":"2016","unstructured":"Gualtierotti R, Ingegnoli F, Griffini S, Grovetti E, Meroni PL, Cugno M. Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade. Clin Exp Rheumatol. 2016;34:451\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"1118_CR9","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s12185-012-1191-x","volume":"96","author":"M Matsuoka","year":"2012","unstructured":"Matsuoka M, Majima T, Onodera T, Ieko M, Souri M, Ichinose A, et al. Hemorrhagic-acquired factor XIII deficiency associated with tocilizumab for treatment of rheumatoid arthritis. Int J Hematol. 2012;96:781\u20135.","journal-title":"Int J Hematol"},{"key":"1118_CR10","doi-asserted-by":"publisher","first-page":"e69944","DOI":"10.1371\/journal.pone.0069944","volume":"8","author":"S Mokuda","year":"2013","unstructured":"Mokuda S, Murata Y, Sawada N, Matoba K, Yamada A, Onishi M, et al. Tocilizumab induced acquired factor XIII deficiency in patients with rheumatoid arthritis. PLoS ONE. 2013;8:e69944.","journal-title":"PLoS ONE"},{"key":"1118_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.thromres.2016.02.026","volume":"140","author":"M Souri","year":"2016","unstructured":"Souri M, Mokuda S, Inanami H, Osaki T, Takasugi K, Ichinose A. Non-autoimmune combined factor XIII A and B subunit deficiencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody (tocilizumab). Thromb Res. 2016;140:100\u20135.","journal-title":"Thromb Res"},{"key":"1118_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1042\/CS20120233","volume":"124","author":"VR Richardson","year":"2013","unstructured":"Richardson VR, Cordell P, Standeven KF, Carter AM. Substrates of Factor XIII-A: roles in thrombosis and wound healing. Clin Sci (Lond). 2013;124:123\u201337.","journal-title":"Clin Sci (Lond)."},{"key":"1118_CR13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1055\/s-0033-1349221","volume":"39","author":"F Peyvandi","year":"2013","unstructured":"Peyvandi F, Menegatti M, Palla R. Rare bleeding disorders: worldwide efforts for classification, diagnosis, and management. Semin Thromb Hemost. 2013;39:579\u201384.","journal-title":"Semin Thromb Hemost"},{"key":"1118_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1055\/s-0036-1571343","volume":"42","author":"JR Byrnes","year":"2016","unstructured":"Byrnes JR, Wolberg AS. Newly-recognized roles of factor XIII in thrombosis. Semin Thromb Hemost. 2016;42:445\u201354.","journal-title":"Semin Thromb Hemost"},{"key":"1118_CR15","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1182\/blood-2014-08-594754","volume":"125","author":"H Raghu","year":"2015","unstructured":"Raghu H, Cruz C, Rewerts CL, Frederick MD, Thornton S, Mullins ES, et al. Transglutaminase factor XIII promotes arthritis through mechanisms linked to inflammation and bone erosion. Blood. 2015;125:427\u201337.","journal-title":"Blood"},{"key":"1118_CR16","doi-asserted-by":"publisher","first-page":"7497","DOI":"10.1002\/jcp.26603","volume":"233","author":"H Sun","year":"2018","unstructured":"Sun H, Kaartinen MT. Transglutaminase activity regulates differentiation, migration and fusion of osteoclasts via affecting actin dynamics. J Cell Physiol. 2018;233:7497\u2013513.","journal-title":"J Cell Physiol"},{"key":"1118_CR17","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569\u201381.","journal-title":"Arthritis Rheum"},{"key":"1118_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van\u2019t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44\u20138.","journal-title":"Arthritis Rheum"},{"key":"1118_CR19","first-page":"S93","volume":"23","author":"J Fransen","year":"2005","unstructured":"Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23:S93\u20139.","journal-title":"Clin Exp Rheumatol"},{"key":"1118_CR20","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/annrheumdis-2013-204767","volume":"73","author":"IA van den Oever","year":"2014","unstructured":"van den Oever IA, Sattar N, Nurmohamed MT. Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system. Ann Rheum Dis. 2014;73:954\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1118_CR21","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11010-018-3326-8","volume":"448","author":"L Balogh","year":"2018","unstructured":"Balogh L, Katona E, Mezei ZA, Kallai J, Gindele R, Edes I, et al. Effect of factor XIII levels and polymorphisms on the risk of myocardial infarction in young patients. Mol Cell Biochem. 2018;448:199\u2013209.","journal-title":"Mol Cell Biochem"},{"key":"1118_CR22","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3390\/ijms16011143","volume":"16","author":"ZA Mezei","year":"2015","unstructured":"Mezei ZA, Bereczky Z, Katona E, Gindele R, Balogh E, Fiatal S, et al. Factor XIII B subunit polymorphisms and the risk of coronary artery disease. Int J Mol Sci. 2015;16:1143\u201359.","journal-title":"Int J Mol Sci"},{"key":"1118_CR23","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1160\/TH06-11-0676","volume":"97","author":"Z Voko","year":"2007","unstructured":"Voko Z, Bereczky Z, Katona E, Adany R, Muszbek L. Factor XIII Val34Leu variant protects against coronary artery disease. A meta-analysis. Thromb Haemost. 2007;97:458\u201363.","journal-title":"Thromb Haemost"},{"key":"1118_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000206026","volume":"76","author":"J Kloczko","year":"1986","unstructured":"Kloczko J, Wojtukiewicz M, Bielawiec M, Zarzycka B, Kinalska I. Plasma factor XIII and some other haemostasis parameters in patients with diabetic angiopathy. Acta Haematol. 1986;76:81\u20135.","journal-title":"Acta Haematol"},{"key":"1118_CR25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/0049-3848(88)90141-7","volume":"51","author":"J Kloczko","year":"1988","unstructured":"Kloczko J, Wojtukiewicz M, Bielawiec M, Zuch A. Alterations of haemostasis parameters with special reference to fibrin stabilization, factor XIII and fibronectin in patients with obliterative atherosclerosis. Thromb Res. 1988;51:575\u201381.","journal-title":"Thromb Res"},{"key":"1118_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2337\/diacare.23.5.703","volume":"23","author":"MW Mansfield","year":"2000","unstructured":"Mansfield MW, Kohler HP, Ariens RA, McCormack LJ, Grant PJ. Circulating levels of coagulation factor XIII in subjects with type 2 diabetes and in their first-degree relatives. Diabetes Care. 2000;23:703\u20135.","journal-title":"Diabetes Care"},{"key":"1118_CR27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3324\/haematol.10647","volume":"92","author":"Z Bereczky","year":"2007","unstructured":"Bereczky Z, Balogh E, Katona E, Czuriga I, Edes I, Muszbek L. Elevated factor XIII level and the risk of myocardial infarction in women. Haematologica. 2007;92:287\u20138.","journal-title":"Haematologica"},{"key":"1118_CR28","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1182\/blood-2018-06-820738","volume":"133","author":"M Menegatti","year":"2019","unstructured":"Menegatti M, Peyvandi F. Treatment of rare factor deficiencies other than hemophilia. Blood. 2019;133:415\u201324.","journal-title":"Blood"},{"key":"1118_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.autrev.2013.08.001","volume":"13","author":"M Cugno","year":"2014","unstructured":"Cugno M, Gualtierotti R, Tedeschi A, Meroni PL. Autoantibodies to coagulation factors: from pathophysiology to diagnosis and therapy. Autoimmun Rev. 2014;13:40\u20138.","journal-title":"Autoimmun Rev"},{"key":"1118_CR30","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/annrheumdis-2018-214894","volume":"78","author":"S Finzel","year":"2019","unstructured":"Finzel S, Kraus S, Figueiredo CP, Regensburger A, Kocijan R, Rech J, et al. Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis. Ann Rheum Dis. 2019;78:1186\u201391.","journal-title":"Ann Rheum Dis"},{"key":"1118_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/BF01419952","volume":"16","author":"A Plenz","year":"1996","unstructured":"Plenz A, Fritz P, Konig G, Laschner W, Saal JG. Immunohistochemical detection of factor XIIIa and factor XIIIs in synovial membranes of patients with rheumatoid arthritis or osteoarthritis. Rheumatol Int. 1996;16:29\u201336.","journal-title":"Rheumatol Int"},{"key":"1118_CR32","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/acr.22765","volume":"68","author":"J Wang","year":"2016","unstructured":"Wang J, Devenport J, Low JM, Yu D, Hitraya E. Relationship between baseline and early changes in C-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:882\u20135.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"1118_CR33","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0140-6736(13)61670-0","volume":"382","author":"C Gabay","year":"2013","unstructured":"Gabay C, Kavanaugh A, Investigators A. Tocilizumab versus adalimumab for rheumatoid arthritis\u2014authors\u2019 reply. Lancet. 2013;382:395.","journal-title":"Lancet"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01118-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01118-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01118-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T23:49:45Z","timestamp":1603496985000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01118-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1118"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01118-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,25]]},"assertion":[{"value":"4 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}